We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $84.77, moving -1.91% from the previous trading session. This move lagged the S&P 500's daily gain of 0.1%. Elsewhere, the Dow gained 0.28%, while the tech-heavy Nasdaq lost 0.09%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 2.45% over the past month. This has outpaced the Medical sector's gain of 1.23% and the S&P 500's loss of 3.6% in that time.
Wall Street will be looking for positivity from Gilead Sciences as it approaches its next earnings report date. On that day, Gilead Sciences is projected to report earnings of $1.50 per share, which would represent year-over-year growth of 117.39%. Our most recent consensus estimate is calling for quarterly revenue of $6.57 billion, down 9.29% from the year-ago period.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $7.09 per share and revenue of $26.46 billion. These results would represent year-over-year changes of -2.61% and -3.08%, respectively.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Gilead Sciences currently has a Zacks Rank of #2 (Buy).
Digging into valuation, Gilead Sciences currently has a Forward P/E ratio of 12.18. For comparison, its industry has an average Forward P/E of 17.52, which means Gilead Sciences is trading at a discount to the group.
Also, we should mention that GILD has a PEG ratio of 0.79. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.32 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 56, which puts it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $84.77, moving -1.91% from the previous trading session. This move lagged the S&P 500's daily gain of 0.1%. Elsewhere, the Dow gained 0.28%, while the tech-heavy Nasdaq lost 0.09%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 2.45% over the past month. This has outpaced the Medical sector's gain of 1.23% and the S&P 500's loss of 3.6% in that time.
Wall Street will be looking for positivity from Gilead Sciences as it approaches its next earnings report date. On that day, Gilead Sciences is projected to report earnings of $1.50 per share, which would represent year-over-year growth of 117.39%. Our most recent consensus estimate is calling for quarterly revenue of $6.57 billion, down 9.29% from the year-ago period.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $7.09 per share and revenue of $26.46 billion. These results would represent year-over-year changes of -2.61% and -3.08%, respectively.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Gilead Sciences currently has a Zacks Rank of #2 (Buy).
Digging into valuation, Gilead Sciences currently has a Forward P/E ratio of 12.18. For comparison, its industry has an average Forward P/E of 17.52, which means Gilead Sciences is trading at a discount to the group.
Also, we should mention that GILD has a PEG ratio of 0.79. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.32 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 56, which puts it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.